Automation is key to ensuring long-term success. Embracing automation is a critical business decision; it will streamline ...

California, US AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25 billion, that ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a ...

Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...

After years of wrangling, OxyContin manufacturer Purdue Pharma is on the brink of a bankruptcy agreement that could allow it ...

As a tech lover, I soak it all in and leave inspired about what’s next. This was the case recently when I attended Google ...

Results from a late-stage trial of Boehringer Ingelheim and Zealand Pharma's GLP-1 and glucagon agonist drug survodutide ...

Merck KGaA has started working with Remepy on the development of hybrid drugs that combine a medicine with digital ...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with John Holodnak, co-founder of Occam, about how AI is ...

From effective panellist recruitment and robust validation, to precision targeting and enhanced engagement, discover how a ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in ...